Back to today’s briefing

Story perspectives

Claudin 18.2: Key Biomarker for Targeted Cancer Therapies

2/25/2025

37 4

Summary

Story summary

Claudin 18.2 emerges as a vital biomarker for gastric and gastroesophageal cancers, paving the way for targeted therapies such as zolbetuximab, which gained approval in 2024. Despite its straightforward testing process, many oncologists overlook it. Boosting awareness and education around claudin testing is crucial to enhance patient access to these life-saving treatments and ongoing clinical trials.

1 of 1

Story summary

Claudin 18.2 emerges as a vital biomarker for gastric and gastroesophageal cancers, paving the way for targeted therapies such as zolbetuximab, which gained approval in 2024. Despite its straightforward testing process, many oncologists overlook it. Boosting awareness and education around claudin testing is crucial to enhance patient access to these life-saving treatments and ongoing clinical trials.